

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number
WO 01/48183 A2(51) International Patent Classification⁷:

C12N 15/00

(74) Agent: BAYLISS, Geoffrey, Cyril; Boult Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(21) International Application Number:

PCT/EP00/13149

(22) International Filing Date:

22 December 2000 (22.12.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GII, GM, IIR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(30) Priority Data:

9930691.2 24 December 1999 (24.12.1999) GB

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


(72) Inventors; and

(75) Inventors/Applicants (for US only): PLAETINCK, Geert [BE/BF]; Pontstraat 16, B-9820 Merelbeke (BF). MORTIER, Katherine [BE/BF]; Paddenhoek 20, B-9830 St.-Martens-Latem (BE). LISSENS, Ann [BE/BF]; Tiensesteenweg 137, B-3010 Kessel-Lo (BE). BOGAERT, Thierry [BE/BF]; Wolvendreef 26g, B-8500 Kortrijk (BE).

Published:

Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/48183 A2

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNAINHIBITION

The present invention is concerned with ways of
5 improving the efficiency of double stranded RNA
inhibition as a method of inhibiting gene expression
in nematode worms such as *C. elegans*. In particular,
the invention relates to the finding that the
susceptibility of nematode worms such as *C. elegans* to
10 double stranded RNA inhibition is affected by changes
in the genetic background of the worms.

It has recently been described in *Nature* Vol 391,
pp.806-811, February 98, that introducing double
stranded RNA into a cell results in potent and
15 specific interference with expression of endogenous
genes in the cell, which interference is substantially
more effective than providing either RNA strand
individually as proposed in antisense technology. This
specific reduction of the activity
20 of the gene was also found to occur in the nematode
worm *Caenorhabditis elegans* (*C. elegans*) when the RNA
was introduced into the genome or body cavity of the
worm.

The present inventors have utilized the double
25 stranded RNA inhibition technique and applied it
further to devise novel and inventive methods of (i)
assigning functions to genes or DNA fragments which
have been sequenced in various projects, such as, for
example, the human genome project and which have yet
30 to be accorded a particular function, and (ii)
identifying DNA responsible for conferring a
particular phenotype. Such methods are described in
the applicant's co-pending application number WO
00/01846. Processes for introducing RNA into a living
35 cell, either *in vivo* or *ex vivo*, in order to inhibit
expression of a target gene in that cell are

additionally described in WO 99/32619.

Several different experimental approaches can be used to introduce double-stranded RNA into nematode worms in order to achieve RNA interference *in vivo*.

5 One of the most straightforward approaches is simple injection of double-stranded RNA into a body cavity. A more elegant solution is to feed the nematodes on food organisms, generally bacteria, which express a double stranded RNA of the appropriate sequence,
10 corresponding to a region of the target gene.

The present inventors have now determined that the phenomenon of RNA interference in nematodes following ingestion of food organisms capable of expressing double-stranded RNA is dependent both on
15 the nature of the food organism and on the genetic background of the nematodes themselves. These findings may be exploited to provided improved methods of double-stranded RNA inhibition.

Therefore, according to a first aspect of the
20 present invention there is provided a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence
25 substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild
30 type.

Caenorhabditis elegans is the preferred nematode worm for use in the method of the invention although the method could be carried out with other nematodes and in particular with other microscopic nematodes,
35 preferably microscopic nematodes belonging to the genus *Caenorhabditis*. As used herein the term "microscopic" nematode encompasses nematodes of

approximately the same size as *C. elegans*, being of the order 1mm long in the adult stage. Microscopic nematodes of this approximate size can easily be grown in the wells of a multi-well plate of the type 5 generally used in the art to perform mid- to high-throughput screening.

It is an essential feature of this aspect of the invention that the nematode has a non wild-type 10 genetic background which confers greater sensitivity to RNA interference phenomena (abbreviated herein to RNAi) as compared to the equivalent wild type nematodes. As illustrated in the accompanying 15 examples, introduction of double-stranded RNA (abbreviated herein to dsRNA) into a non wild-type strain according to the invention results in greater inhibition of expression of the target gene. Depending on the nature of the target gene, this greater level of inhibition may be detectable at the 20 phenotypic level as a more pronounced phenotype.

The nematode having non wild-type genetic background may, advantageously, be a mutant strain. Mutations which have the effect of increasing 25 susceptibility of the nematode to RNAi may, for example, affect the stability of dsRNA or the kinetics of dsRNA turnover within cells of the worm or the rate of uptake of dsRNA synthesised by a food organism. Suitable mutant strains include mutant strains 30 exhibiting knock-out or loss-of-function mutations in one or more genes encoding proteins involved in RNA synthesis, RNA degradation or the regulation of these processes.

In one preferred embodiment, the nematode is a 35 mutant strain, more preferably a mutant *C. elegans*, which exhibits reduced activity of one or more nucleases compared to wild-type. Suitable strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding

nucleases, such as RNases. A particularly preferred example is the *nuc-1* strain. This mutant *C. elegans* strain is known *per se* in the art.

In a second preferred embodiment, the nematode is 5 a mutant strain, more preferably a mutant *C. elegans*, which exhibits increased gut uptake compared to wild-type. Particularly preferred examples of such strains are the so-called *C. elegans* gun mutants described herein. In a still further embodiment, the nematode 10 may be a transgenic worm comprising one or more transgenes which increase gut uptake relative to wild-type.

The term "increased gut uptake" as used herein is taken to mean increased uptake of foreign particles 15 from the gut lumen and may encompass both increased gut permeability and increased gut molecular transport compared to wild-type *C. elegans*.

C. elegans feeds by taking in liquid containing its food (e.g. bacteria). It then spits out the 20 liquid, crushes the food particles and internalises them into the gut lumen. This process is performed by the muscles of the pharynx. The process of taking up liquid and subsequently spitting it out is called pharyngeal pumping. Once the food particles have been 25 internalised via pharyngeal pumping their contents must cross the gut itself in order to reach target sites in the worm. There are multiple factors which effect the uptake of compounds from the gut lumen to the surrounding tissues. These include the action of multi-drug resistance proteins, multi-drug resistance related proteins and the P450 cytochromes as well as other enzymes and mechanisms available for transport 30 of molecules through the gut wall.

C. elegans mutants which exhibit increased uptake 35 of foreign molecules through the gut may be obtained from the *C. elegans* mutant collection at the *C.*

elegans Genetic Center, University of Minnesota, St Paul, Minnesota, or may be generated by standard methods. Such methods are described by Anderson in Methods in Cell Biology, Vol 48, "C. elegans: Modern 5 biological analysis of an organism" Pages 31 to 58. Several selection rounds of the PCR technique can be performed to select a mutant worm with a deletion in a desired gene. Alternatively, a population of worms could be subjected to random mutagenesis and worms 10 exhibiting the desired characteristic of increased gut uptake selected using a phenotypic screen, such as the dye uptake method described herein.

As an alternative to mutation, transgenic worms 15 may be generated with the appropriate characteristics. Methods of preparing transgenic worms are well known in the art and are particularly described by Craig Mello and Andrew Fire, Methods in Cell Biology, Vol 48, Ed. H.F. Epstein and D.C. Shakes, Academic Press, pages 452-480.

20 Worms exhibiting the desired characteristics of increased gut uptake can be identified using a test devised by the inventors based on uptake of a marker precursor molecule which is cleaved by the action of enzymes present in the gut lumen to generate a marker 25 molecule which produces a detectable signal, such as fluorescence. A suitable marker precursor molecule is the fluorescent dye precursor BCECF-AM available from Molecular Probes (Europe BV), Netherlands. This dye only becomes fluorescent when cleaved by esterases and 30 maintained at a pH above 6. The pH of the gut lumen is usually 5 or below. Thus, any BCECF-AM taken up through the pharynx into the gut lumen is not 35 fluorescent until cleaved and the cleaved portion has entered the cells surrounding the lumen which are at a higher pH. Thus, this dye is able to quickly identify mutant or otherwise modified worms which have increased gut transport or permeability. There is a

gradual increase in fluorescence in the tissues surrounding the gut while the gut lumen remains dark. The fluorescence can be detected at an excitation wavelength of 485 nm and an emission wavelength of 530
5 nm.

Specific examples of gun mutant strains isolated using this procedure which may be used in the method of the invention are strains bg77, bg84, bg85 and bg86, although it is to be understood that the
10 invention is in no way limited to the use of these specific strains. The *C. elegans* gun mutant strain bg85 was deposited on 23 December 1999 at the BCCM/LMG culture collection, Laboratorium Voor Microbiologie, Universiteit Gent, K. L. Ledeganckstraat 35, B-9000, Gent, Belgium under accession number LMBP 5334CB. The
15 phrase "the bg85 mutation" as used herein refers to the specific mutation(s) present in the bg85 strain which is/are responsible for conferring the gun phenotype.

It is also within the scope of the invention to use a non wild-type nematode strain, preferable a *C. elegans* strain, having multiple mutations which affect sensitivity to RNAi. A preferred type of multiple mutant is one having at least one mutation which
20 results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type. An example of such a mutant is a *C. elegans* strain having the *nuc-1* mutation and at least one further gun
25 mutation. As exemplified herein, double mutants having the *nuc-1* mutation and a gun mutation exhibit enhanced sensitivity to RNAi as compared to either
30 *nuc-1* or gun single mutants.

For the avoidance of doubt, where particular
35 characteristics or properties of nematode worms are described herein by relative terms such as "enhanced"

or "increased" or "decreased" this should be taken to mean enhanced, increased or decreased relative to wild-type nematodes. In the case of *C. elegans*, wild-type is defined as the N2 Bristol strain which is well known to workers in the *C. elegans* field and has been extremely well characterised (see Methods in Cell Biology, Volume 48, *Caenorhabditis elegans: Modern biological analysis of an organism*, ed. by Henry F. Epstein and Diane C. Shakes, 1995 Academic Press; The nematode *Caenorhabditis elegans*, ed. by William Wood and the community of *C. elegans* researchers., 1988, Cold Spring Harbor Laboratory Press; *C. elegans II*, ed. by Donald L. Riddle, Thomas Blumenthal, Barbara J. Meyer and James R. Priess, 1997, Cold Spring Harbor Laboratory Press). The N2 strain can be obtained from the *C. elegans* Genetic Center, University of Minnesota, St Paul, Minnesota, USA.

The food organism for use in the above aspect of the invention is preferably a bacterium such as, for example, a strain of *E.coli*. It will, however, be appreciated that any other type of food organism on which nematodes feed and which is capable of producing dsRNA could be used. The food organism may be genetically modified to express a double-stranded RNA of the appropriate sequence, as will be understood with reference to the examples included herein. One convenient way in which this may be achieved in a bacterial food organism is by transforming the bacterium with a vector comprising a promoter or promoters positioned to drive transcription of a DNA sequence to RNA capable of forming a double-stranded structure. Examples of such vectors will be further described below.

The actual step of feeding the food organism to the nematode may be carried out according to procedures known in the art, see WO 00/01846.

Typically the feeding of the food organisms to the nematodes is performed on standard agar plates commonly used for culturing *C. elegans* in the laboratory. However, the step of feeding the food 5 organism to the nematodes may also be carried out in liquid culture, for example in the wells of 96-well microtitre assay plates.

The inventors have further observed that variations in the food organism can result in enhanced 10 *in vivo* RNAi when the food organism is ingested by a nematode worm.

Accordingly, in a further aspect the invention provides a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said 15 nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a 20 modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

The modification present in the food organism can be any modification which results in increased 25 expression of the dsRNA or in increased persistence of the dsRNA. Suitable modifications might include mutations within the bacterial chromosome which affect RNA stability and/or degradation or mutations which have a direct effect on the rate of transcription. In 30 a preferred embodiment, the food organism is an RNase III minus *E. coli* strain, or any other RNase negative strain.

According to a still further aspect of the invention there is provided a method of inhibiting 35 expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide

sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

5 In addition to exhibiting increased sensitivity to RNAi following feeding with food organisms capable of expressing a dsRNA, nematodes which exhibit increase gut uptake as described herein also show increased uptake of DNA molecules capable of producing
10 double-stranded RNA structures following ingestion into a nematode.

In a preferred embodiment, the DNA is in the form of a vector comprising a promoter or promoters orientated to relative to a sequence of DNA such that
15 they are capable of driving transcription of the said DNA to make RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to the promoter or promoters.

Several different arrangements of promoters may
20 be used in such a vector. In a first arrangement a DNA fragment corresponding to a region of the target gene is flanked by two opposable polymerase-specific promoters which are preferably identical. Transcription from the opposable promoters produces
25 two complementary RNA strands which can anneal to form an RNA duplex. The plasmid pGN1 described herein is an example of a vector comprising two opposable T7 promoters flanking a multiple cloning site for insertion of a DNA fragment of the appropriate
30 sequence, corresponding to a region of a target gene. pGN8 is an example of a vector derived from pGN1 containing a fragment of the *C. elegans* unc-22 gene. In an alternative arrangement, DNA fragments
35 corresponding to a region of the target gene may be placed both in the sense and the antisense orientation downstream of a single promoter. In this case, the sense/antisense fragments are co-transcribed to

generate a single RNA strand which is self-complementary and can therefore form an RNA duplex.

In both of the above arrangements, the polymerase-specific T3, T7 and SP6 promoters, all of 5 which are well known in the art, are useful for driving transcription of the RNA. Expression from these promoters is dependent on expression of the cognate polymerase. Advantageously, the nematode itself may be adapted to express the appropriate 10 polymerase. Expression of the polymerase may be general and constitutive, but could also be regulated under a tissue-specific promoter, an inducible promoter, a temporally regulated promoter or a promoter having a combination of such characteristics. 15 Transgenic *C. elegans* strains harboring a transgene encoding the desired polymerase under the control of an appropriately-regulated promoter can be constructed according to methods known *per se* in the art and described, for example, by Craig Mello and Andrew Fire 20 in Methods in Cell Biology, Vol 48, Ed. H. F. Epstein and D. C. Shakes, Academic Press, pp 452-480.

The advantage of adapting the nematode to express the required polymerase is that it is possible to control inhibition of expression of the target gene in 25 a tissue-specific and/or temporally specific manner by placing expression of the polymerase under the control of an appropriately regulated promoter.

Introduction of DNA into nematodes in accordance with the method of the invention can be achieved using 30 a variety of techniques, for example by direct injection into a body cavity or by soaking the worms in a solution containing the DNA. If the DNA is in the form of a vector as described herein, e.g. a plasmid harboring a cloned DNA fragment between two flanking 35 T7 promoters, then dsRNA corresponding to this DNA fragment will be formed in the nematode resulting in down regulation of the corresponding gene. The

introduced DNA can form an extrachromosomal array, which array might result in a more catalytic knock-out or reduction of function phenotype. The DNA might also become integrated into the genome of the nematode, 5 resulting in the same catalytic knock out or reduction of function phenotype, but which is stably transmittable.

In each aspect of the invention, the double-stranded RNA structure may be formed by two separate 10 complementary RNA strands or a single self-complementary strand, as described above. Inhibition of target gene expression is sequence-specific in that only nucleotide sequences corresponding to the duplex region of the dsRNA structure are targeted for 15 inhibition.

It is preferred to use dsRNA comprising a 20 nucleotide sequence identical to a portion of the target gene, although RNA sequences with minor variations such as insertions, deletions and single base substitutions may also be used and are effective for inhibition. It will be readily apparent that 100% sequence identity between the dsRNA and a portion of the target gene is not absolutely required for inhibition and the phrase "substantially identical" as 25 used herein is to be interpreted accordingly.

Generally sequences which are substantially identical will share at least 90%, preferably at least 95% and more preferably at least 98% nucleic acid sequence 30 identity. Sequence identity may be conveniently calculated based on an optimal alignment, for example using the BLAST program accessible at WWW.ncbi.nlm.nih.gov.

The invention will be further understood with reference to the following non-limiting Examples, 35 together with the accompanying Figures in which:

Figure 1 is a plasmid map of the vector pGN1

containing opposable T7 promoters flanking a multiple cloning site and an ampicillin resistance marker.

5 Figure 2 is a plasmid map of the vector pGN8 (a genomic fragment of the *C. elegans* unc-22 gene cloned in pGN1).

10 Figure 3 is a plasmid map of the vector pGN29 containing two T7 promoters and two T7 terminators flanking *Bst*XI sites. This vector permits cloning of DNA fragments linked to *Bst*XI adaptors.

15 Figure 4 is a plasmid map of the vector pGN39 containing two T7 promoters and two T7 terminators flanking attR recombination sites (based on the Gateway™ cloning system of Life Technologies, Inc).

20 Figure 5 is a plasmid map of the vector pGX22 (a fragment of the *C. elegans* gene C04H5.6 cloned in pGN29).

25 Figure 6 is a plasmid map of the vector pGX52 (a fragment of the *C. elegans* gene K11D9.2b cloned in pGN29).

Figure 7 is a plasmid map of the vector pGX104 (a fragment of the *C. elegans* gene Y57G11C.15 cloned in pGN29).

30 Figure 8 is a plasmid map of the vector pGZ8 (a fragment of the *C. elegans* gene T25G3.2 cloned in pGN39).

35 Figure 9 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the

plasmid pGX22.

Figure 10 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 5 liquid culture were fed with *E. coli* containing the plasmid pGX52.

Figure 11 shows the results of an RNAi experiment in 10 which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the plasmid pGXGZ8.

Figure 12 shows the results of an RNAi experiment in 15 which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the plasmid pGX104

Example 1

Influence of genetic background on the efficiency of RNAi in *C. elegans*.

5 **Introduction**

Various different *C. elegans* strains were fed with different bacteria, to test the possibility of RNAi by feeding *C. elegans* with bacteria that produce dsRNA.

10 The possibility of DNA delivery and dsRNA delivery has previously been envisaged by using different bacterial strains. In this experiment the importance of the *C. elegans* strain as receptor of the dsRNA is also shown.

15 For this experiment the following *E. coli* strains were used:

1. MC1061: F- *araD139* Δ (*ara-leu*)7696 *galE15* *galK16* Δ (*lac*)*X74* *rpsL* (*Str^r*) *hsdR2* (*r_k⁻ m_k⁺*) *mcrA* *mcrB1*
 - regular host for various plasmids,
 - Wertman et al., (1986) Gene 49:253-262,
 - Raleigh et al., (1989) in Current Protocols in Molecular Biology eds. Ausubel et al, Publishing associates and Wiley Interscience; New York. Unit 1.4.
2. B21(DE3): F- *ompT(lon)* *hsdS_B* (*r_B⁻,m_B⁻*; an *E. coli* B strain) with DE3, a λ prophage carrying the T7 RNA polymerase gene.
 - regular host for IPTG inducible T7 polymerase expression,
 - Studier et al. (1990) Meth. Enzymol. 185:60-89
3. HT115 (DE3): F- *mcrA* *mcrB* IN(*rrnD-rrnE*) 1 λ -*rnc14::tr10* (DE3 lysogen: lacUV5 promoter-T7polymerase)
 - host for IPTG inducible T7 polymerase

expression,
- RNaseIII-,
- Fire A, Carnegie Institution, Baltimore, MD,
Pers. Comm.

5

For this experiment the following *C. elegans* strains were used:

1. *C. elegans* N2: regular WT laboratory strain
- 10 2. *C. elegans* *nuc-1*(e1393): *C. elegans* strain with a reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death; ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described: e1392 (strong allele: has been used for the experiments described below); n887 (resembles e1392) and n334 (weaker allele)
 - Stanfield et al. (1998) East Coast Worm meeting abstract 171,
 - Anonymous, Worm Breeder's Gazette 1(1):17b
 - Hevelone et al. (1988) Biochem. Genet. 26:447-461
 - Ellis et al., Worm breeder's Gazette 7(2):44
 - Babu, Worm Breeder's gazette 1(2):10
- 15 20 25 - Driscoll, (1996) Brain Pathol. 6:411-425
- Ellis et al., (1991) Genetics 129:79-94

For this experiment the following plasmids were used:

- 30 pGN1: A vector encoding for ampicillin resistance, harbouring a multiple cloning site between two convergent T7 promoters.
- 35 pGN8: pGN1 containing a genomic fragment of *unc-22*. Decreased *unc-22* expression via RNAi results in a "twitching" phenotype in *C. elegans*.

Experimental conditions

12-well micro-titer plates were filled with approximately 2 ml of NGM agar per well (1 litre of NGM agar: 15g Agar, 1g peptone, 3g NaCl, 1ml 5 cholesterol solution (5 mg/ml in EtOH), with sterile addition after autoclaving of 9.5 ml 0.1M CaCl₂, 9.5 ml 0.1 ml MgSO₄, 25 ml 1M KH₂PO₄/K₂HPO₄ buffer pH 6 and 5 ml nystatin solution (dissolved 10 mg/ml in 1:1 EtOH:CH₃COONH₄ 7.5 M).

10 The dried plates were spotted with approximately 50 µl of an overnight culture of bacteria. When IPTG induction was required, 50 µl of a 10 mM stock solution of IPTG was dropped on top of the bacteria 15 lawn, and incubated at 37°C for approximately 4 hours. Individual nematodes at the L4 growth stage were then placed in single wells. In each well 4 nematodes, and the plates were further incubated at 20°C for 6 days to allow offspring to be formed. The F1 offspring of 20 the seeded nematodes were tested for the twitching phenotype.

Results

Table 1: Percentage of the offspring that show the twitching phenotype

	MC1061	N2	<i>nuc-1</i>
5	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	0%	0%
	pGN8 + IPTG	0%	0%
10	BL21 (DE3)		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	20% (+)	>90% (++)
	pGN8 + IPTG	20% (+)	>90% (++±)
15	HT115 (DE3)		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	50% (+±)	>90% (++)
	pGN8 + IPTG	80% (++)	>90% (+++)
20			

%: percentage twitchers

+: weak twitching

++: twitching

+++: strong twitching

25

Conclusions

The experiment with *E. coli* MC1061 shows that no twitching could be observed in this experiment.

30

Neither the N2 nematodes nor the *nuc-1* nematodes showed any twitchers. This is to be expected as *E. coli* MC1061 does not produce any T7 RNA polymerase, and hence the unc-22 fragment cloned in pGN8 is not

expressed as dsRNA.

The experiment with *E. coli* strain BL21(DE3) and nematode strain N2 shows expected results. BL21(DE3) harbouring plasmid pGN1 does not result in any twitching as the pGN1 vector is an empty vector. BL21 (DE3) harbouring PGN8 results in the expression of unc-22 dsRNA. When this dsRNA is fed to the N2 nematode (indirectly by feeding with the bacteria that produce the dsRNA), this results in a twitching phenotype, indicating that the dsRNA is able to pass the gut barrier and is able to perform its interfering activity.

Surprisingly the RNAi effect of the unc-22 dsRNA was even more pronounced in *C. elegans* strain *nuc-1* than in the wild type N2 strain. Although one may expect that the *nuc-1* mutation results in the non-degradation or at least in a slower degradation of DNA, as the NUC-1 protein is known to be involved in DNase activity, we clearly observe an enhancement of the RNAi induced phenotype in *C. elegans* with a *nuc-1* background. The *nuc-1* mutation has not been cloned yet, but it has been described that the gene is involved in nuclease activity, and more particularly DNase activity. If the NUC-1 protein is a nuclease, it may also have activity on nuclease activity on dsRNA, which would explain the enhanced RNAi phenotype. The *nuc-1* gene product may be a nuclease, or a regulator of nuclease activity. As the mode of action of RNAi is still not understood, it is also possible that the NUC-1 protein is interfering in the mode of action of RNAi. This would explain why a *nuc-1* mutant is more sensitive to RNAi.

35

The experiment with the *E.coli* strain HT115 (DE3)

confirms the experiments with the BL21(DE3) strain. The RNA interference observed with the unc-22 dsRNA is even higher. In comparison with strain BL21(DE3) this could be expected, as HT115(DE3) is a RNase III minus 5 strain, and hence is expected to produce larger amounts of dsRNA, resulting in more prominent RNAi. This indicates further that the RNAi observed in this experiment is the result of the dsRNA produced by the bacteria fed to the *C. elegans*. Feeding *C. elegans* 10 *nuc-1* with HT115(DE3) harbouring pGN8 also results in higher RNA interference phenotype than feeding the same bacteria to *C. elegans* wild-type strain N2. Once again this indicates that improved RNAi can be realised using a nuclease negative *C. elegans* and more 15 particularly with a *C. elegans nuc-1* (e1392) strain.

Summary

RNA interference can be achieved in *C. elegans* by 20 feeding the worms with bacteria that produce dsRNA. The efficiency of this RNA interference is dependent both on the *E. coli* strain and on the genetic background of the *C. elegans* strain. The higher the level of dsRNA production in the *E. coli*, the more 25 RNAi is observed. This can be realised by using efficient RNA expression systems such as T7 RNA polymerase and RNAase negative strains, such as RNaseIII minus strains. In this example the level of dsRNA production varied: HT115(DE3)>BL21(DE3)>MC1061. 30 RNA interference is high in *C. elegans* strains that are nuclease negative, or that are influenced in their nuclease activity. This can be realised by using a mutant strain such as *C. elegans nuc-1*. 35 In this example the sensitivity to RNAi varied: *C. elegans nuc-1* >> *C. elegans N2*

Example 2

Improved RNAi by feeding dsRNA producing bacteria in selected *C. elegans* strains-Comparison of the *nuc-1* strain with several mutants which show improved gut uptake (designated herein 'gun' mutants). Strains bg77, bg78, bg83, bg84, bg85, bg86, bg87, bg88 and bg89 are typical gun mutant *C. elegans* strains isolated using selection for increased gut uptake (gun phenotype) with the marker dye BCECF-AM.

10

Experimental conditions:

- 12-well micro-titer plates were filled with approximately 2ml of NGM agar (containing 1ml/l of ampicillin (100 μ g/ml) and 5 ml of 100mM stock IPTG) per well
- the dried plates were spotted with 25 μ l of an overnight culture of bacteria (BL21DE3/HT115DE3) containing the plasmids pGN1 (T7prom-T7prom) or pGN8 (T7prom-unc-22-T7prom)
- individual nematodes at the L4 growth stage were then placed in single wells, one nematode per well
- the plates were incubated at 20°C for 6 days to allow offspring to be formed
- the adult F1 offspring of the seeded nematodes were tested for the twitching phenotype

Results:

Table 2:

20°C/6d	pGN1 HT115DE3	pGN8- BL2DE3	pGN8- HT115DE3	
N2	0	1	1	
<i>nuc-1</i>	0	1-2	3	
<i>bg77</i>	0	1-2	2-3	
<i>bg78</i>	0	1	1-2	
<i>bg83</i>	0	1	1	
<i>bg84</i>	0	1-2	3	
<i>bg85</i>	0	1	2-3	
<i>bg86</i>	0	1	2-3	
<i>bg87</i>	0	1	1	
<i>bg88</i>	0	1	1	
<i>bg89</i>	0	1	1	

figure legend:

- 0 = no twitching
- 20 1 = no to weak phenotype
- 2 = clear phenotype
- 3 = strong phenotype

25 **Conclusions**

- bacterial strain HT115(DE3) shows a better RNAi sensitivity than bacterial strain BL21(DE3)
- the *nuc-1* *C. elegans* strain is a better strain than the Wild-type N2 strain for RNAi sensitivity
- 30 - various gun mutants (improved gut uptake mutants) and more particularly the gun mutant strains bg77, bg84, bg85, bg86 show improved sensitivity to RNAi compared to Wild-type.

A double mutant *C. elegans* strain (nuc-1/gun) shows even greater sensitivity to RNAi compared to wild-type:

5 Double mutants were constructed to test the prediction that gun/nuc mutants would even show more enhanced RNAi sensitivity. As an example, the crossing strategy with gun strain bg85 is shown, similar crosses can be conducted with other gun strains, such
10 as bg77, bg84 and bg86.

P0 cross: gun(bg85) x WT males

F1 cross: nuc-1 x gun(bg85)/+ males

15 F2 cross: nuc-1 x gun(bg85)/+; nuc-1/0 males (50%)
nuc-1 x +/++; nuc-1/0 males (50%)

20 F3 single: gun(bg85)/+; nuc-1 hermaphrodites (25%)
+/++; nuc-1 hermaphrodites (75%)

F4 single: gun(bg85); nuc-1 (1/4 of every 4th
plate high staining with BCECF)

25 F5 retest: gun(bg85); nuc-1 (100% progeny of F4
singled high staining with BCECF)

30 To select for the gun phenotype, the fluorescence precursor BCECF-AM is used (obtainable from Molecular probes). The precursor BCECF-AM is cleaved by esterases present in the gut of the worm to generate the dye BCECF which is fluorescent at pH values above 6. This allows selection for worms that have a gun phenotype. BCECF-AM is taken up through the pharynx
35 into the gut lumen and is not fluorescent until it has been cleaved, and the BCECF portion has entered the

cells surrounding the lumen. Wild-type worms will show slower or no increase in BCECF fluorescence.

5 **Example 3**

Improved RNAi feeding in liquid culture using *nuc-1*(e1393) *C. elegans*.

Introduction

10 N2 and *nuc-1* *C.elegans* strains were fed with bacteria producing dsRNAs that give lethal phenotypes via RNAi. For this example RNAi was performed in liquid culture instead of on agar plates. We show here for a number of genes that the RNAi effect is more penetrant using 15 the *nuc-1* strain than the N2 strain, and that RNAi can be performed in liquid.

For this experiment the following *E.coli* strains were used:

20

1. HT115 (DE3): F- *mcrA mcrB IN(rrnD-rrnE)* 1 λ -*rnc14::tr10* (DE3 lysogen: lacUV5 promoter -T7 polymerase)
 - host for IPTG inducible T7 polymerase expression
 - RNaseIII-
 - Fire A, Carnegie Institution, Baltimore, MD, Pers. Comm.

30

For this experiment, following *C. elegans* strains were used:

35

1. *C. elegans* N2: regular WT laboratory strain
2. *C. elegans* *nuc-1*(e1393): *C. elegans* strain with a reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death;

ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described: e1392 (strong allele: has been used for the experiments described below); n887 (resembles e1392) and n334 (weaker allele)

5 - Stanfield et al. (1998) East Coast Worm meeting abstract 171

- Anonymous, Worm Breeder's Gazette 1(1):17b

- Hevelone et al. (1988) Biochem. Genet. 26:447-461

10 - Ellis et al., Worm breeder's Gazette 7(2):44

- Babu, Worm Breeder's gazette 1(2):10

- Driscoll, (1996) Brain Pathol. 6:411-425

- Ellis et al., (1991) Genetics 129:79-94

15

For this experiment, the following plasmids that all give lethal phenotypes in *C. elegans* via RNAi were used:

20 pGX22: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid C04H5.6 corresponding to a member of the RNA helicase family.

25 pGX52: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid K11D9.2b corresponding to sarco/endoplasmic Ca^{2+} ATPase also known as SERCA.

30 pGZ18: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid T25G3.2 corresponding to a chitin like synthase gene.

35 pGX104: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid Y57G11C.15 corresponding to sec-61, a transport protein.

Experimental conditions

- 1 ml overnight cultures of HT115 (DE3) bacteria containing the plasmids pGX22, pGX52, pGZ18 or pGX104 respectively were pelleted and resuspended
5 in S-complete medium, containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.

- 10 µl of this bacterial solution was transferred to a 96-well microtiter plate already filled with
10 100 µl S-complete containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.

- 3 nematodes at the L1 growth stage of N2 and nuc-1 strain were then placed in single wells, 3
15 L1's per well. Per experimental set up, 16 wells were used (n=16).

- the plates were incubated at 25°C for 5 days to allow offspring to be formed.
20

- the plates were visually checked and the following phenotypes could be scored per individual well:
25 **no effect:** L1's developed to adults and gave normal offspring.

no F1 offspring: L1's developed to adults and gave no offspring.
30 **acute lethal:** original L1 did not mature and died.

Results

35 The results of this experiment are illustrated graphically in Figures 9 to 12. Data are expressed as

a percentage of the total (n=16) on the y-axis for both N2 and *nuc-1* strains.

Conclusions

5 The following genes were tested in this liquid RNAi assay:

- C04H5.6: an RNA helicase. RNAi of this gene interferes with the generation of offspring.
- 10 - SERCA: a sarco/endoplasmic Ca^{2+} ATPase. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- 15 - T25G3.2: a chitin like synthase gene. RNAi of this gene causes dead eggs.
- sec-61: a transport protein. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- 20 - RNAi can be performed under liquid conditions.

As in the previous examples this set of experiments shows that the *nuc-1* *C. elegans* strain is more sensitive to RNAi than the wild-type N2 strain. This 25 is most clear for less penetrant phenotypes such as SERCA and chitin synthase. For strong RNAi phenotypes like the helicase and Sec-61 the difference between the N2 wild-type strain and the *nuc-1* stain is less pronounced.

Example 4**Cloning of pGX22, pGX52, pGZ18 and pGX104 for RNAi**

A set of primers for each gene was designed on the basis of sequence data available in the publicly

5 accessible *C. elegans* sequence database (Acedb).

The cosmid names relate to:

10 1. **C04H5.6**=member of RNA helicase
2. **K11D9.2b**=SERCA
3. **Y57G11C.15**=transport protein sec-61
4. **T25G3.2**=chitin synthase like

The following primer sequences were designed:

15 1. **C04H5.6F** 5'-TGCTCAGAGAGTTCTAACGAAACC-3'
C04H5.6R 5'-CAATGTTAGTTGCTAGGACCACCTG-3'

2. **K11D9.2bF** 5'-CAGCCGATCTCCGTCTTGTG-3'
K11D9.2bR 5'-CCGAGGGCAAGACAAACGAAG-3'

3. **Y57G11C.15F** 5'-ACCGTGGTACTCTTATGGAGCTCG-3'
Y57G11C.15R 5'-TGCAGTGGATTGGGTCTTCG-3'

25 4. **T25G3.2F**
5'-GGGGACAAGTTGTACAAAAAGCAGGCTATGCCAAGTACATGTCGATTGCG-3'

T25G3.2R

5'-GGGGACCACCTTGTACAAGAAAGCTGGGTTGGAGAAGCATTCCGAGAGTTG-3'

30

PCR was performed on genomic DNA of N2 strain *C. elegans* to give PCR products of the following sizes:

35 1326bp for C04H5.6
1213bp for K11D9.2b

1024bp for Y57G11C.15

1115bp for T25G3.2

The PCR fragments of C04H5.6, K11D9.2b and Y57G11C.15
5 were linked to *Bst*XI adaptors (Invitrogen) and then
cloned into the pGN29 vector cut with *Bst*XI. pGN29
contains two T7 promoters and two T7 terminators
flanking a cloning site which is adapted for
facilitated cloning of PCR fragments, comprising a
10 stuffer DNA flanked by two *Bst*XI sites (see schematic
Figure 3). The resulting plasmids were designated
pGX22 (C04H5.6), pGX52 (K11D9.2b) and pGX104
(Y57G11C.15).

15 The PCR fragment of T25G3.2 was cloned into pGN39 via
recombination sites based on the GATEWAY™ cloning
system (Life Technologies, Inc). pGN39 contains two
T7 promoters and two T7 terminators flanking a cloning
site which facilitates "High Throughput" cloning based
20 on homologous recombination rather than restriction
enzyme digestion and ligation. As shown schematically
in Figure 4, the cloning site comprises *att*R1 and
*att*R2 recombination sites from bacteriophage lambda
flanking a gene which is lethal to *E. coli*, in this
25 case the *ccdB* gene. This cloning site is derived from
the Gateway™ cloning system commercially available
from Life Technologies, Inc. The Gateway™ cloning
system has been extensively described by Hartley et
al. in WO 96/40724 (PCT/US96/10082).

Example 5

Selecting *C. elegans* mutations for increased gut uptake (gun) using marker dye BCECF-AM and *unc-31* as background.

5

The screen was performed in *unc-31*(e928) mutant background, to ensure high amounts of dye in the gut lumen, since *unc-31* mutations show constitutive pharyngeal pumping. The dye (BCECF-AM: 2',7' bis (2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethylester), obtained from Molecular Probes, is cleaved by intracellular esterases. Fluorescence accumulates in the gut cells upon passage through the apical gut membrane.

15

Mutagenesis

Day 1: *unc-31* L4 staged worms were mutagenised with EMS (final concentration 50 mM) for 4 hours

Day 2: P0 was divided over several large agar plates

Day 6: F1's were collected and dropped on large plates. The number of eggs the F1's layed were checked every hour and de F1's were removed when 10-20 eggs per F1 were counted

25 Day 10: F2 adults were collected and screened with BCECF-AM. Mutations with increased staining of the gut cells after 15-30 minutes exposure to the dye were selected and singled on small agar plates.

30

About 50 initial positives gave progeny which was retested with BCECF-AM (2x) and leucine CMB (1x) 9 of the 50 strains were kept (2 strains : 3 times positive, 7 other strains : twice positive)

35

Table 3: Isolation of mutations for increased staining with BCECF-AM

5	Total P0	Total F1	Total F2	screened chromosomes	number of strains isolated
	(counted)	(estimated)	(calculated)	(estimated)	(counted)
	2251	55618	222472	100000	9

Outcrossing, backcrossing and double construction

10 1. backcrossing *unc-31; gun* --> *unc-31; gun*
 - *unc-31; gun* x WT males
 - singled 2x5 WT hermaphrodites F1s (*unc-31/+; gun/+*)
 - singled 50 WT hermaphrodites F2s (1/4 homozygous)
 - select strains segregating 1/4 unc
 15 - stain unc strains with BCECF-AM
 - from positive strains pick unc homozygous
 - retest 100 % unc strains with BCECF-AM
 - kept 1 strain (backcrossed)

20 2. *unc-31* background was crossed out-->+; *gun*
 - *unc-31; gun* x WT males
 - singled 2x5 WT hermaphrodites F1s (*unc-31/+; gun/+*)
 - singled 50 WT hermaphrodites F2s (1/4 homozygous)
 - select strains which did not segregate unc F3s
 25 anymore
 - stain non unc strains with BCECF-AM
 - 7 positive strains were retested with BCECF-AM and finally 1 was selected and kept (outcrossed)

30 3. +; *gun* (1x outcrossed) were 2 times backcrossed-->+; *gun* (3x backcrossed)
 - *gun* x WT males
 - WT hermaphrodites x F1 males (*gun/+*)
 - singled 10 WT hermaphrodites F2s (1/2 heterozygous)
 35 - singled 50 WT hermaphrodites F3s (1/8 homozygous)

- 31 -

- stain strains with BCECF-AM- retested positives with BCECF-AM and finally 1 was selected and kept

4. *gun* (3x backcrossed) were crossed with *nuc-1*(X)

5 mutant--> *gun*; *nuc-1*

- *gun* x WT males
- *nuc-1* x *gun*/+ males
- *nuc-1* x *gun*/+; *nuc-1*/0 or +/++; *nuc-1*/0 males
- singled 10 WT hermaphrodite progeny (*nuc-1* homozygous, ½ heterozygous *gun*)
- singled 40 WT hermaphrodite progeny (1/8 homozygous *gun*)
- stain strains with BCECF-AM
- retested positives with BCECF-AM and finally 1 was

15 selected and kept

Table 6: Strains derived from *gun* mutations

20	<i>gun</i>	<i>unc-31</i> ; <i>gun</i>		<i>unc-31</i> ; <i>gun</i>		<i>+</i> ; <i>gun</i>			<i>gun</i> ; <i>nuc-1</i>
		original isolate		backcrossed (1x)		outcrossed (1x)		3x b.c.	from 3x b.c.
	allele number	isolation number	strain number	isolation number	strain number	isolation number	strain number	strain number	strain number
	bg77	31.4	UG 510	31.4.46.1	UG 556	31.4.34	UG 563	UG 674	UG 777
25	bg78	37.5	UG 511	37.5.46.4	UG 557	37.5.15	UG 564	UG 675	-
	bg83	10.2	UG 543	10.2.11	UG 600	10.2.21	UG 586	UG 676	-
	bg84	7.2	UG 544	7.2.10	UG 601	7.2.15	UG 589	UG 677	UG 774
	bg85	11.5	UG 545	11.5.29.2	UG 602	2x b.c.	UG 717		UG 775
30	bg86	42.1	UG 546	42.1.4.5	UG 603	42.1.18	UG 587	UG 678	UG 776
	bg87	7.1	UG 547	7.1.8.3	UG 604	7.1.22	UG 585	UG 679	-
	bg88	5.3	UG 548	5.3.9	UG 605	5.3.18	UG 584	UG 680	-
	bg89	23.4	UG 549	23.4.13.5	UG 606	23.4.3	UG 588	UG 671	-

SEQUENCE LISTING:

SEQ ID NO: 1 complete sequence of pGN1

5 SEQ ID NO: 2 complete sequence of pGN8

SEQ ID NO: 3 complete sequence of pGN29

10 SEQ ID NO: 4 complete sequence of pGN39

SEQ ID NO: 5 complete sequence of pGX22

SEQ ID NO: 6 complete sequence of pGX52

15 SEQ ID NO: 7 complete sequence of pGX104

SEQ ID NO: 8 complete sequence of pGZ8

SEQ ID NO: 9 primer C04H5.6F

20 SEQ ID NO: 10 primer C04H5.6R

SEQ ID NO: 11 primer K11D9.2bF

25 SEQ ID NO: 12 primer K11D9.2bR

SEQ ID NO: 13 primer Y57G11C.15F

SEQ ID NO: 14 primer Y57G11C.15R

30 SEQ ID NO: 15 primer T25G3.2F

SEQ ID NO: 16 primer T25G3.2R

Claims:

1. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to 5 said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode 10 has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild type.
2. A method as claimed in claim 1 wherein the 15 nematode is a microscopic nematode.
3. A method as claimed in claim 2 wherein the nematode is from the genus *Caenorhabditis*.
- 20 4. A method as claimed in claim 3 wherein the nematode is *C. elegans*.
5. A method as claimed in any one of claims 1 to 4 wherein the nematode has a mutant genetic 25 background.
- 30 6. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits reduced activity of one or more nucleases compared to wild type.
7. A method as claimed in claim 6 wherein the nematode is *C. elegans* strain *nuc-1*.
- 35 8. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits increased

gut uptake compared to wild type.

9. A method as claimed in claim 8 wherein the nematode is mutant *C. elegans* strain bg85.

5

10. A method as claimed in claim 5 wherein the nematode is a mutant strain having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type.

11. A method as claimed in claim 10 wherein the nematode is a mutant *C. elegans* strain having the *nuc-1* mutation and the bg85 mutation.

15

12. A method as claimed in any one of the preceding claims wherein the food organism has been engineered to express a double-stranded RNA.

20

13. A method as claimed in any one of the preceding claims wherein the food organism is a bacterium.

25

14. A method as claimed in claim 13 wherein the food organism is *E. coli*.

30

15. A method as claimed in any one of the preceding claims wherein the food organism has been genetically modified to express a double-stranded RNA having a nucleotide sequence substantially identical to a portion of said target gene.

35

16. A method as claimed in claim 15 wherein the food organism contains a DNA vector, the vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of

initiating transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

5

17. A method as claimed in claim 25 wherein the vector comprises two promoters flanking the DNA sequence.

10

18. A method as claimed in claim 26 wherein the two promoters are identical.

15

19. A method as claimed in claim 25 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

20

20. A method as claimed in any one of claims 16 to 20 wherein the nematode or the food organism is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

25

21. A method as claimed in any one of claims 16 to 20 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

30

22. A method as claimed in any one of claims 1 to 21 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

35

23. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a

portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

24. A method as claimed in claim 23 wherein the food organism is a bacterium.

10

25. A method as claimed in claim 24 wherein the bacterium is an *E. coli* strain.

15

26. A method as claimed in claim 25 wherein the *E. coli* strain is an RNase III minus strain or any other RNase negative strain.

20

27. A method as claimed in any one of claims 23 to 26 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

25

28. A method of inhibiting expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

30

29. A method as claimed in claim 28 wherein the nematode is a microscopic nematode.

35

30. A method as claimed in claim 29 wherein the nematode is from the genus *Caenorhabditis*.

31. A method as claimed in claim 30 wherein the

nematode is *C. elegans*.

32. A method as claimed in any one of claims 28 to 31 wherein the nematode has a mutant genetic
5 background.

33. A method as claimed in claim 32 wherein the nematode is mutant *C. elegans* strain bg85.

10 34. A method as claimed in any one of claims 28 to 33 wherein the DNA capable of producing a double-stranded RNA structure is a vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of initiating
15 transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

20 35. A method as claimed in claim 34 wherein the vector comprises two promoters flanking the DNA sequence.

25 36. A method as claimed in claim 35 wherein the two promoters are identical.

30 37. A method as claimed in claim 34 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

35 38. A method as claimed in any one of claims 34 to 37 wherein the nematode is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

39. A method as claimed in any one of claims 34

to 38 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

FIG. 1




FIG. 2.




FIG. 3.




FIG. 4.




FIG. 5.




FIG. 6.




FIG. 7.




FIG. 8.




FIG. 9.




FIG. 10.




FIG. 11.





FIG. 12.



1
SEQUENCE LISTING

<110> DEVGEN NV

<120> IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

<130> SCB/53711/001

<140>

<141>

<160> 14

<170> PatentIn Ver. 2.0

<210> 1

<211> 3216

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGN1

<400> 1

gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcata 60
ggcgaaattt taaacgttaa tattttgtta aaattcgcgt taaaatattt ttaaatcagc 120
tcattttta accaataggc cgaaatcggc aaaatccctt ataaatcaaa agaatagacc 180
gagatagggt tgagtgtgt tccagttgg aacaagagtc cactattaaa gaacgtggac 240
tccaacgtca aaggcgaaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 300
cccaaataa gtttttgcg gtcgaggtgc cgtaaagctc taaatcgaa ccctaaaggg 360
agcccccgat ttagagcttgc acggggaaag ccggcgaacg tggcgagaaa ggaagggaaag 420
aaagcgaaaag gagcggggcgc tagggcgctg gcaagtgtag cggtcacgct gcgcgttaacc 480
accacacccg cgcgcctaa tgcgcgcata cagggcgctg ccattcgcca ttcaggctgc 540
gcaactgttgc ggaaggcgaa tcggtgcggg cctcttcgcatttacgcag ctggcgaaaag 600
ggggatgtgc tgcaaggcgaa ttaagttggg taacgcagg gtttcccgat tcacgacgtt 660
gtaaaacgcg ggcgcgtgaa ttgttaatacg actcactata gggcgaattc gagctcggt 720
cccggggatc ctctagagtc gaaagcttct cgcctatag tgagtctgtat tacagcttga 780
gtattctata gtgtcaccta aatacgcttgc cgtaatcatg gtcatacgctg tttcctgtgt 840
gaaattgtta tccgcctaca attccacaca acatacgagc cggaagcata aagtgtaaaag 900
cctggggatgc ctaatgagtg agctaactca cattaattgc gttgcgtca ctgcccgcctt 960
tccagtcggg aaacctgtcg tgccagctgc attaatgaat cggccaacgc gcggggagag 1020
gcgggttgcg tattgggcgc tcttccgcattt cctcgctcac tgactcgctg cgctcggtcg 1080
ttcggctcgcg gcgagcgta tcagctact caaaggcggt aatacggtt tccacagaat 1140
caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgtt 1200
aaaaggccgc gttgctgctg ttttcgata ggctccggcc ccctgacgag catcacaaaa 1260
atcgacgctc aagtcaaggagg tggcgaaacc cgacaggact ataaagatac caggcgtttc 1320
cccctggaaag ctcctcgatcg cgcctctcgatcg ttccgcacctt ggcgcattacc ggataccgtt 1380
ccgccttct ccttcggaa agcggtggcgc ttctcatag ctacgcgtgt aggtatctca 1440
gttcgggtat ggtcggtcg tccaaagctgg gctgtgtgc cgaaccccccc gttcagcccc 1500
accgctgcgc cttatccgtt aactatcgatcg ttgagtccaa cccggtaaaga cacgacttat 1560
cgccactggc agcagccact ggtAACAGGA ttagcagagc gaggtatgtt ggcgggtgc 1620
cagagttctt gaagtggggg cctaactacg gctacactag aaggacagta tttggtatct 1680
gcgcctctgtc gaagccagtt accttcggaa aaagagtgg tagctttgtt tccggcaaacc 1740
aaaccaccgc tggtagcggt ggttttttgc ttgcaagca gcagattacg cgcaaaaaaa 1800
aaggatctca agaagatcct ttgatctttt ctacgggtc tgacgctcag tggAACGAAA 1860
actcacgtta agggattttg gtcatacgat tatcaaaaaag gatcttcacc tagatccctt 1920
taaattaaaa atgaagttt aaatcaatct aaagtatac ttagttaact tggctcgaca 1980

2

gttaccaatg	cttaatcagt	gaggcaccta	tctcagcgat	ctgtcttattt	cgttcatcca	2040
tagttgcctg	actccccgtc	gtgtagataa	ctacgatacg	ggagggctta	ccatctggcc	2100
ccagtgtcgc	aatgataccg	cgagacccac	gctcacccgc	tccagattt	tcagcaataa	2160
accagccagc	cggaagggcc	gagcgcagaa	gtggccctgc	aactttatcc	gcctccatcc	2220
agtctattaa	ttgttgcgg	gaagctagag	taagtagttc	gccagttat	agtttgcgca	2280
acgttgttgg	cattgtctaca	ggcatctgtgg	tgtcacgctc	gtcgtttgg	atggcttcat	2340
tcagctccgg	ttcccaacga	tcaaggcgag	ttacatgatc	ccccatgttg	tgcaaaaaaag	2400
cggtagctc	cttcggctt	ccgatcggtt	tcagaagtaa	gttggccgca	gtgttatcac	2460
tcatggttat	ggcagcactg	cataattctc	ttactgtcat	gccatccgta	agatgcttt	2520
ctgtgactgg	tgagttactca	accaagtcat	tctgagaata	ccgcgcccgg	cgaccgagtt	2580
gctttgccc	ggcgtcaata	cgggataata	gtgtatgaca	tagcagaact	ttaaaagtgc	2640
tcatcattgg	aaaacgttct	tcggggcgaa	aactctcaag	gatcttaccg	ctgttgagat	2700
ccagttcgat	gtaacccact	cgtgcaccca	actgtatcc	agcatcttt	actttcacca	2760
gcgttctgg	gtgagcaaaa	acaggaaggc	aaaatgcgc	aaaaaaggga	ataagggcga	2820
cacggaaatg	ttgaataactc	atactttcc	tttttcaata	ttattgaagc	atttatcagg	2880
gttattgtct	catgagcgga	tacatatttg	aatgtattta	gaaaaataaa	caaatagggg	2940
ttccgcgcac	atttccccga	aaagtgcac	ctgacgtcta	agaaaccatt	attatcatga	3000
cattaaccta	taaaaaatagg	cgtatcacga	ggcccttcg	tctcgcgcgt	ttcggtgatg	3060
acggtgaaaa	cctctgacac	atgcagctcc	cggagacggt	cacagttgt	ctgtaaagcgg	3120
atgccgggag	cagacaagcc	cgtcagggcg	cgtcagcggg	tgttggcggg	tgtcggggct	3180
ggcttaacta	tgcggcatca	gagcagattt	tactga			3216

<210> 2

<211> 4620

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGN8

<400> 2

gatccgaatc	tccatgtctg	ttaacagcct	tgacacgaa	tttatattca	tgccctttag	60
tcaaatcgtc	aacgtgaaag	ttggtatcc	tgctctctcc	gcaagcagtc	catctgcccag	120
tggcagcata	ttgccttca	atgacatagt	gactgattt	agtcctcca	tcatcttctg	180
gttccttcca	tgcaagatca	catccatctt	tgacaatatt	agtacatcg	agaggtccac	240
gtggcttga	tggatgatca	agaacagtaa	ccttcacttc	agcagtgtca	gttccattct	300
cgttctctgc	tttgatgata	tagttccctg	tatccgaacg	caaagctctc	ttcacatgga	360
atttagtctt	gcccgttca	ttgttcaact	tcatacgtatc	atcagattcg	actggtgttc	420
cttcgaaagt	ccaagtaatt	gttggagttt	gttcaccact	gactggaatg	ttcaatgaga	480
agtcttgc	agccttgacc	ttgatttctt	gaatcgagtt	acgatcgatg	actggtgaa	540
ctataattt	attcaatgt	tattagtaat	tgatttagac	tcttaccatt	tctagccctt	600
gcaacagctg	atgctgaatc	agatggatct	cccaatcctg	ccttggttctt	ggcacggatt	660
ctgaattcgt	actttgatcc	ttcccttgaga	tttccaacag	tagattcgt	ttgtccagct	720
ggaacatgag	caacgtcatt	ccagaatggc	gagaactcgt	ccttcatctc	aacaacgtat	780
tcctcgattt	gaggaccacc	gtcgtttgc	gttggcttcc	attcaagggtc	aacatgatcc	840
ttatccaaat	cagtaattt	aggagcattt	gtctttctg	gcttgc当地	tggatctttg	900
gcaagtgtgg	ttccgaaggt	ctccaatgg	tcggactctc	cttcagcatt	gacggcagcg	960
acacggaaact	aaaaatcaaa	atgtttagg	caatttgat	caagattaa	aaattctcac	1020
tttatattca	tgtccaggaa	taagaccgtc	aacaacagct	gtatctt	ctccagcgc	1080
ctttgcagct	ggaacccatc	ttccacttgc	agtatcgatc	tttcgatca	catagtttc	1140
aatttggaaata	cctccatcat	catctggtgc	acgccaattt	aaagtgcac	gatcaccatg	1200
aacatcgaa	acatctaatg	gaccatttgg	agaagttgc	ttgtctgaaa	atttaaaata	1260
taaccaaatt	aattgaagaa	aactaatgtc	caccaataac	attgatctt	acagttgtt	1320
catcttctcc	atttgcattt	acagtttgc	tagtgaatgt	tccactgtct	ccacgttcca	1380
tttgccttac	aaccagctt	gattttgtt	ctgggttac	aagcttctcg	ccctataatg	1440
agtcttattt	cagcttgcgt	atttgcattt	gtcacctaaa	tagcttggcg	taatcatgtt	1500
catacgctt	tcctgtgtga	aatttttac	cgctcacaat	tccacacaaac	atacgagccg	1560
gaagcataaa	gtgtaaagcc	tgggtgcct	aatgagtttgc	ctaactcaca	ttaattgcgt	1620

三

<210> 3
<211> 4756
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pGX22

<400> 3

catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tggtagatc 3420
 cagttcgatg taacccactc gtgcacccaa ctgatcttca gcacatttta ctttcaccag 3480
 cgttctggg tgagcaaaaa caggaaggca aaatgccca aaaaaggaa taaggcgac 3540
 acggaaatgt tgaatactca tactcttcct tttcaatat tattgaagca ttatcaggg 3600
 ttattgtctc atgagcgat acatatttg atgtatttag aaaaataaac aaatagggt 3660
 tccgcgcaca ttccccgaa aagtgcacc tgacgtctaa gaaaccatata ttatcatgac 3720
 attaacctat aaaaataaggc gtatcacgag gccccttcgt ctgcgcgtt tcggtgatga 3780
 cggtgaaaac ctctgacaca tgcagctccc ggagacggc acagcttgc tgtaagcgga 3840
 tgccgggagc agacaagccc gtcaggcgc gtcagcggtt gttggcggtt gtcgggctg 3900
 gcttaactat gcggcatcg agcagattgt actgagatg caccatatgc ggtgtgaaat 3960
 accgcacaga tgcgtaaagg gaaaataccg catcaggcga aattgtaaac gttaatattt 4020
 tgttaaaatt cgcgttaat attgttaaa tcagctcatt ttttaaccaa taggcccggaa 4080
 tcggcaaaat cccttataaa tcaaaaagaat agaccgagat agggttgagt gttgttccag 4140
 tttggaaacaa gagtccacta ttaaagaacg tggactccaa cgtcaaaaggcg cggaaaaccg 4200
 tctatcaggg cgatggccca ctacgtgaac catcacccaa atcaagttt ttgcggtcga 4260
 ggtgccgtaa agctctaaat cggaaacccta aagggagccc ccgatttaga gcttgacggg 4320
 gaaagccgcg gAACGTGGCG agaaaggaag ggaagaaagc gaaaggagcgg ggcgctaggg 4380
 cgctggcaag ttagcgcgc acgctgcgcg taaccaccac accccgcgcg cttaatgcgc 4440
 cgctacaggc cgctccatt cggcattcag gctgcgcac ttttggaaag ggcgatcggt 4500
 gccccctct tcgcttattac gccagctggc gaaagggggta ttttgcgcac ggcgattaaag 4560
 ttggtaacg ccagggtttt cccagtcacg acgtttaaa acgacggccca gtgaatttga 4620
 atacgactca ctataggcg aattcaaaaa acccctcaag acccggttttag agggcccaag 4680
 gggttatgtct agtgaatttgc gcagggttacc cggggatcct ctagagatcc ctcgaccccg 4740
 agatccattt tgctgg 4756

<210> 4

<211> 4643

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX52

<400> 4

gagtgccacca tatgcgggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcacca 60
 ggcgaaattt gaaacgttaa tattttgtta aaattcgcgt taaaatattt ttaaatcagc 120
 tcattttta accaataggc cgaaatcgcc aaaaatccctt ataaatcaaa agaatagacc 180
 gagatagggt tgagtgttgt tccagttgg aacaagagtc cactattaaa gaaacgtggac 240
 tccaaacgtca aaggcgaaa aaccgtctat caggcgatg gcccactacg tgaaccatca 300
 cccaaatcaa gtttttgcg gtcgagggtgc cgtaaagctc taaaatcgaa ccctaaagg 360
 agcccccgat ttagagcttgc acggggaaag ccggcgaacg tggcgagaaa ggaagggaaag 420
 aaagcgaaag gagcgggccc tagggcgctg gcaagtgtac cggtcacgcg ggcgtaacc 480
 accacaccccg ccgcgtctaa tgcgcgccta cagggcgctg ccattcgcca ttcaggctgc 540
 gcaactgttgc ggaaggcgca tcggtgcggg ccttcgcgtt attacgcac gtcggcggaaag 600
 ggggatgtgc tgcaaggcgca ttaagttggg taacgcgcagg gttttcccg tcacgcacgtt 660
 gtaaaaacgc ggcgcgtgaa ttgttaatcgt actcactata gggcgaattc aaaaaacccc 720
 tcaagaccccg tttagaggccc ccaagggtt atgctagtac attctgcagg gtacccgggg 780
 atccctctaga gatcccctcgat cctcgagatc cattgtgcgt gcagccgatc tccgtcttgt 840
 gaagatctac tccaccacca tccgtatcgat tcagtcacat ctcaccggag aatctgtgtc 900
 ttttatcaag cacaccgact ctgtgcgcata tccacgcgt gttaaccagg acaagaagaa 960
 ttgtctgttc tcgggaacca atgtcgatc tggaaaggct cgtggaaatcg tcttcggaaac 1020
 cggattgacc actgaaatcg gaaagatccg taccgaaatg gtcgagaccg agaatgagaa 1080
 gacaccactt caacagaatg tggacgaaat cggagagcaa ctttccaagg ttatctctgt 1140
 tatttgcgtt gctgtttggg ctatcaacat tggacatttca aacgatcccg ctcacgggtgg 1200
 atcatgggtt aaggcgacaa tctactactt caaaatcgcc gttgcgttgc cctgcgtgc 1260
 tattccagaa ggacttccag ctgtcatcac cacgtgcctt gccctcgaa ctcgcgtat 1320
 ggcacaagaag aacgcttatttgc taagatccct tccatccgtc gaaactcttgc gatgcacatc 1380
 ttttatctgc tctgacaaga ctggaaactctt caccaccaac cagatgtctg ttttggaaat 1440

gttcatcgct ggacaaggctt ctggagacaa catcaacttc accgagttcg ccatctccgg 1500
 atccacctac gagccagtcg gaaaggttc caccaatgga cgtaaatca acccagctgc 1560
 tggagaattc gaatcactca ccgagttgc catgatctgc gctatgtca atgattcatc 1620
 tggattac aatgagacca agaagatcta cgagaaatgc ggagaagcca ctgaaactgc 1680
 tcttacgtt cttgctgaga agatgaatgt tttcggacc tcgaaagccg gactttcacc 1740
 aaaggagctc ggaggagttt gcaaccgtgt catccaacaa aaatggaaga aggagttcac 1800
 actcgagttc tcccgtgatc gtaaatccat gtccgcctac tgcttccag ctccggagg 1860
 atctggagcc aagatgtcg tgaaggagc cccagaagga gtctcgaa gatgcaccca 1920
 cgtcagagtt aacggacaaa aggttccact cacctctgcc atgactcaga agattgtta 1980
 ccaatgcgtg caatacgaaa ccgaaagaga taccctcgt tgcgttgcct tcggccagca 2040
 caatggatct cgagggatct tccatataccat ccagttctgc gcctgcaggt cgccgcccgc 2100
 actctctaga cgcgtaaatc tactagcata acccccttgg gcctctaaac gggctttag 2160
 gggtttttg agcttctcgc cctatagtga gtcgttattac agctttagta ttctatagt 2220
 tcacctaataat agcttggcgt aatcatggtc atagctgttt cctgtgtgaa attgttatcc 2280
 gctcacaatt ccacacaaca tacgagccgg aagcataaaatg tggtaaagcct ggggtgccta 2340
 atgagtggc taactcacat taattgcgtt ggcgtcaactg cccgccttcc agtcgggaaa 2400
 cctgtcgtgc cagctgcatt aatgaatccgg ccaacgcgcg gggagaggcg gtttgcgtat 2460
 tggcgctct tccgcttcct cgctactga ctcgctgcgc tcggcgttgc ggctgcgcgc 2520
 agcgtatca gctcactcaa aggccgtaat acggttatcc acagaatcag gggataacgc 2580
 agggaaagaaac atgtgagccaa aaggccagca aaaggccagg aaccgtaaaaa aggccgcgtt 2640
 gctggcggtt ttgcataggc tccggccccc tgacgagcat cacaatccatc gacgctcaag 2700
 tcagagggtgg cggaaacccca caggactata aagataccag gcgttcccc ctggaaagctc 2760
 cctcgtgcgc tctctgttgc cggccctgccc gcttaccggg tacctgtccg ctttctccc 2820
 ttcggaaagc gtggcgctt ctcatagctc acgctgttagg tatctcgtt cgggtgttagt 2880
 cgttcgtcc aagctgggtt gtgtgcacga acccccccgtt cagccgcacc gtcgcgcctt 2940
 atccggtaac ttcgtcttgc agtccaaaccc ggtaaagacac gacttacgtc cactggcagc 3000
 agccactgtt aacaggatca gcagagcggg gtagttaggc ggtgtacag agttcttggaa 3060
 gtggggcct aactacggct acactagaag gacagtattt ggtatctgcg ctctgctgaa 3120
 gccaattacc ttccggaaaaa gagttggtag ctcttgatcc ggcaaaacaaa ccaccgttgg 3180
 tagcgggtgtt tttttgttt gcaaggcggca gattacgcgc agaaaaaaaag gatctcaaga 3240
 agatccttgc atctttctca cggggctgca cgcctcgtgg aacggaaaacg cagtttaagg 3300
 gattttggtc atgagattat caaaaaggat cttcaccttag atccttttaa attaaaaatg 3360
 aagttttaaa tcaatctaaa gtatatatga gtaaaacttgg tctgacagtt accaatgtt 3420
 aatcagttag gCACCTATCTCAGCAGTCG TCTATTTCTGT TCTATCCATAG TTGCTGTACT 3480
 ccccgctgtg tagataacta cgatacgggaa gggcttacca tctggccccc gtcgtcaat 3540
 gataccgcga gacccacgct caccggctcc agatttataca gcaataaaacc agccagccgg 3600
 aaggcccgag cgccagaatgt gtcctgcaac tttatccggcc tccatccagt ctattaattt 3660
 ttgcgggaa gctagagtaa gtatgttgcg agttaatagt ttgcgcacg ttgttggcat 3720
 tgctacaggc atcgtgggtt cacgtctgtc gtttggatg gcttcattca gtcgggttc 3780
 ccaacgatca aggccgttta catgatcccc catgttgcg aaaaaagccg ttagctcctt 3840
 cggccctccg atcgttgcgaa gaaatgtt ggccgcagtg ttatcactca tgggtatggc 3900
 agcaactgtt aattcttca ctgtcatgccc atccgttataa tgctttctgt tgactgggtt 3960
 gtactcaacc aagtctttt gagaataccg cggccggcga ccgagttgtc ttggccggc 4020
 gtcaatacgg gataatagt tatgacatag cagaacttta aaagtgcata tcattggaaa 4080
 acgttcttcg gggcgaaaaac tctcaaggat cttaccgttgc ttgagatcca gttcgatgt 4140
 acccaactcgat gCACCTATCTCAGCAGTCG TCTATTTCTGT TCTACCCAGCG TTTCTGGGTG 4200
 agcaaaaaca ggaaggcaaa atgcccggaaa aaaggaaata agggccacac ggaaatgtt 4260
 aataactcata ctcttcctt ttcaatattttt ttgaaggcatt tatcagggtt attgtctcat 4320
 gagccgatc atatttgcattt gtatttagaa aaataaacaa ataggggttc cgccgcacatt 4380
 tccccggaaa gtgccacccgtt acgttcaaga aaccattatt atcatgacat taacctataa 4440
 aaataggcgt atcacgaggc ctttcgttcc cgcgcgttgc ggtgtatgacg gtggaaacct 4500
 ctgacacatg cagctcccg agacggtcac agcttgcgttgc taagccgttgc ccgggagcc 4560
 acaagccgtt cagggcgcgtt cagccgggttgc tggccgggttgc cggggctggc ttaactatgc 4620
 ggcgtatcagag cagattgtac tga 4643

<210> 5

<211> 4454

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX104

<400> 5

gagtgcacca tatgcgttgt gaaataccgc acagatgcgt aaggagaaaa taccgcata 60
 ggcgaaattt gaaacgttaa tattttgtt aaattcgcgt taaatattt ttaaatcagc 120
 tcattttta accaataaggc cgaaatcggc aaaatccctt ataaatcaaa agaatagacc 180
 gagatagggt tgagtgtgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 240
 tccaaacgtca aaggcgaaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 300
 cccaaatcaa gtttttgcg gtcgaggtgc cgtaaagctc taaatcgaa ccctaaaggg 360
 agcccccgat ttagagctt acggggaaag ccggcgaacg tggcgagaaa ggaagggaaag 420
 aaagcgaaag gagcgggccc tagggcgctg gcaagtgtag cggtcacgct gcgcgttaacc 480
 accacaccccg cgcgcttaa tgcgcgcata cagggcgatg ccattcgcca ttcaggctgc 540
 gcaactgtt ggaaggcgca tcggtgcggg cctcttcgct attacgcacg ctggcgaaag 600
 ggggatgtgc tgcaaggcgta ttaagtggg taacgcacgg gtttcccgat tcacgacgtt 660
 gtaaaaacgc ggcgcgtgaa ttgtaaatacg actcactata gggcgaattc aaaaaacccc 720
 tcaagacccg ttttagaggcc ccaagggtt atgctagtga attctgcagg gtacccggg 780
 atcctctaga gatccctcgta cctcgagatc cattgtgtcg gaccgtggta ctcttatgg 840
 gctcggaatc tcgccaatcg tcacttctgg acttatacatg caacttctcg ccggagccaa 900
 gatcatcgaa gtcggagaca caccaaaaggc ccgtgcctt ttcacacggag cccagaaatg 960
 taagccaaa agtgtgtgtt ttcaatctct aatttttggaa ctttcagtg ttcggatatgg 1020
 tcatcactgt tggacaagctt attgtctacg tcatgtccgg actctacggg gagccatcg 1080
 aaatcgagc tggaaatctgt ctccttatcg tcgtccaaact cggtattggc ggtctcatcg 1140
 tcctccttct cgcgcgtt ctccaaaggat gatgtggctt cggatccggg atttctct 1200
 tcattgcac caacatctgt gaaaccattt tctggaaaggc atttccccc gcaacaatga 1260
 acaccggacg tggaaaccggag ttcaaggagc cgcgttatttc tctttccat cttcttgcca 1320
 cccgcgtccga caagggtccgt gcccattcgat aggttttcta ccgtccaaac cttccaaact 1380
 tggatgaaattt gatggctact ttccctcgat ttgcgggtgtt tatttacttc caaggattcc 1440
 gtgtcgaccc cccaaatcaag tctggccgc accgtggaca atacagcagc taccaatca 1500
 agctcttcta cacctccaaatcatttcaatca tccttcaatc tgctctcgat tccaacctct 1560
 acgttatctc tcaggtttgt tgcattctcag tagtaccgtt agatgtttat ctttctctag 1620
 agggtcaagt tggccgagaa aatttttggat ttcattctca agtctgtatgg aaaaatgtta 1680
 tttttcagat gtcggccggaa aagttcgag gaaacttctt catcaacactt ctcggatacc 1740
 ggtccgatata caccggatac agaagctacc caactggagg actctgtac tatcttac 1800
 caccagagtc tcttggacac atcttcaag acccaatcca ctgcaccagc acaatggatc 1860
 tcgagggatc ttccatcacct accagtctcg cgcctgcagg tcgcggccgc gactctctag 1920
 acgcgtaaatc ttactagcat aacccttgg ggcctctaaa cgggtcttgc ggggtttttt 1980
 gagcttctcg ccctatacg tgcgttattt cagtttgcgtt attctatagt gtcaccaatgg 2040
 tagcttggcg taatcatgtt catagctgtt tcctgtgtt aattgttattc cgctcacaat 2100
 tccacacacaac atacgagccg gaagcataaa gtgtaaagcc tgggggtgcct aatgagtgag 2160
 ctaactcaca ttaattgcgt tgcgttact gcccgcattt cagtcgggaa acctgtcg 2220
 ccagctgcata taatgaatcg gccaacgcgc ggggagaggc ggtttgcgtt ttgggcgtc 2280
 ttccgcttcc tcgcttacttgc actcgtctcg ctcggatgtt cggctgcggc gacggatc 2340
 agctcactca aaggcggtaa tacggttatc cacagaatca ggggataacg cagggaaagaa 2400
 catgtgagca aaaggccagc aaaaggccag gaaccgtaaa aaggccgcgt tgctggcg 2460
 tttcgatagg ctccgcggcc ctgacgagca tcacaaaaat cgacgctcaa gtcagagggt 2520
 gcgaaaccccg acaggactat aaagatacca ggcgtttccc cctggaaatcg ccctcgatcg 2580
 ctctcctgtt cgcgccttc cgcattaccgg atacctgtcc gcctttctcc ttccggaaag 2640
 cgtggcgctt tctctatcgat cgcgtgttagt gtatctcagt tcggatgttagg tcgttcgc 2700
 caagctgggc tggatgtgcacg aaccggccgt tcagccgcac cgctgcgcct tatccggtaa 2760
 ctatcgatctt gatgtccaaacc cggtaagaca cgacttatacg ccactggcag cagccactgg 2820
 taacaggatt agcagagcga ggtatgttagg cggatgtaca gaggatcttgc agtgggtggcc 2880
 taactacggc tacactagaa ggacagtattt tggatgttgc gctctgtatcg agccagttac 2940
 cttcggaaaa agagttgtt gctttgtatcg cggcaacacaa accaccgtcg gtagcgggtgg 3000
 ttttttgcgtt tgcaaggcagc agattacgcg cagaaaaaaa ggatctcaag aagatccctt 3060
 gatcttctc acggggatcg acgtctcgatg gaacgaaaac tcacgttaag ggattttgcgtt 3120

catgagatta	tcaaaaagga	tcttcaccta	gatcctttta	aattaaaaat	gaagtttaa	3180
atcaatctaa	agtatataatg	agtaaacttg	gtctgacagt	taccaatgct	taatcagtga	3240
ggcacctatc	tcagcgatct	gtctatttcg	ttcatccata	gttcctgac	tccccgtcgt	3300
gtagataact	acgatacggg	aggcttacc	atctggcccc	agtgtcgaa	tgataccgcg	3360
agacccacgc	tcacccggctc	cagatttata	agcaataaaac	cagccagccg	gaagggccga	3420
gcccagaagt	ggtcctgcaa	cttattccgc	ctccatccag	tctattaatt	gttgcggga	3480
agcttagaga	agtagttcgc	cagttaatag	tttgcgaac	gttggggca	ttgtacagg	3540
catcggttg	tcacgctcg	cgtttggat	ggcttcattc	agctccgggt	cccaacgatc	3600
aaggcgagtt	acatgatccc	ccatgttgc	caaaaaagcg	gttagctcct	tcggtcctcc	3660
gatcggtgc	agaagtaagt	tggccgcagt	gttattcactc	atgttatgg	cagcaactgca	3720
taattctctt	actgtcatgc	catccgtaa	atgcctttct	gtgactgggt	agtactcaac	3780
caagtcatc	tgagaatacc	gcgcggggcg	accgagttgc	tctgccccgg	cgtcaatacg	3840
ggataatagt	gtatgacata	gcagaacttt	aaaagtgc	atcattggaa	aacgttcttc	3900
ggggcggaaa	ctctcaagga	tcttaccgct	gtttagatcc	agttcgatgt	aacccactcg	3960
tgcacccaa	tgatcttcag	catcttttac	tttcaccagc	gttctgggt	gagcaaaaac	4020
aggaaggcaa	aatgcccaca	aaaagggaat	aaggcgaca	cgggaaatgtt	gaatactcat	4080
actcttcctt	tttcaatatt	attdaagcat	ttatcagggt	tattgtctca	tgagcgata	4140
catatttga	tgtatttgc	aaaataaaaca	aatagggggt	ccgcgcacat	ttccccgaaa	4200
agtgccacct	gacgtctaa	aaaccattat	tatcatgaca	ttaacctata	aaaataggcg	4260
tatcacgagg	cccttcgtc	tcgcgcgtt	cggtgtatgc	ggtaaaaaacc	tctgacacat	4320
gcagctcccg	gagacggtca	cagcttgc	gtaaaggat	gccggggagca	gacaagcccg	4380
tcagggcgcg	tcagcggtg	ttggcggtg	tcggggctgg	cttaactatg	cggcatcaga	4440
cgagattgt	ctga					4454

<210> 6

<211> 4701

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGZ18

<400> 6

acccagctt	tttgtacaaa	gtggtgatct	ttccagcaca	atggatctcg	aggatcttc	60
catacctacc	agttctgcgc	ctcgaggctcg	cgccgcgcac	tctctagacg	cgtaagctta	120
ctagcataac	cccttggggc	cctaaacgg	gtcttgggg	gttttttgc	cttctcgccc	180
tatagttagt	cgttattacag	tttgcgtatt	ctatagtc	acctaaatag	cttggcgtaa	240
tcatggtcat	agctgttcc	tgtgtgaaat	ttttatccgc	tcacaattcc	acacaacata	300
cgagccggaa	gcataaaatg	taaaggctgg	ggtgcctaat	gagttagct	actcacat	360
attgcgttgc	gctcaactg	cgcttccag	tcgggaaacc	tgctgtgcca	gctgcattaa	420
tgaatcgcc	aacgcgcggg	gagaggcggt	ttgcgtattt	ggcgccttc	cgcttcctcg	480
ctcaactgact	cgctgcgtc	ggtcgttccg	ctgcggcgag	cggtatcagc	tcactcaaag	540
gcggtaatac	ggttatccac	agaatcagg	gataacgcag	gaaaagacat	gtgagcaaaa	600
ggccagcaaa	aggccagggaa	ccgtaaaaag	gccgcgtgc	tggcggtttt	cgataggctc	660
cgcggccctg	acgagcatca	caaaaaatcg	cgctcaagtc	agaggtggcg	aaacccgaca	720
ggactataaa	gataccaggc	gttccccct	ggaagctccc	tcgtgcgtc	tcctgttccg	780
accctggcc	ttaccggata	cctgtccgc	tttctccct	cgggaaagct	ggcgcttct	840
catagctcac	gctgttaggt	tctcgttgc	gtgttaggtc	ttcgctccaa	gtgggtctgt	900
gtgcacgaac	cccccggtca	gcccgcacgc	tgcccttat	ccggtacta	tcgtcttgc	960
tccaaaccgg	taagacacga	cttacgcaca	ctggcagcag	ccactgttgc	caggattagc	1020
agagcgaggt	atgtaggcg	tgctacagag	ttcttgcgt	ggtggctaa	ctacggctac	1080
actagaagga	cagtatttgg	tatctgcgt	ctgctgaagc	cagttacct	cgaaaaaaga	1140
gttggtagct	tttgatccgg	caaaacaaacc	accgctggta	gcgggtgtt	ttttgtttgc	1200
aagcagcaga	ttacgcgcag	aaaaaaagga	tctcaagaag	atccttgc	cttttctacg	1260
gggtctgacg	ctcagtggaa	cgaaaaactca	cgtaaggaa	ttttggctat	gagattatca	1320
aaaaggatct	tcacctagat	cctttaaat	aaaaatgaa	gttttaatc	aatctaaagt	1380
atatatgat	aaacttgcgc	tgacagttac	caatgcctaa	tcagtgggc	acctatctca	1440
gcgatctgtc	tatccgttc	atccatagtt	gcctgactcc	ccgtcggt	gataactacg	1500

atacgggagg gcttaccatc tggcccccagt gctgaatga taccgcgaga cccacgctca 1560
ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg cagaagtgt 1620
cctgcaactt tatccgcctc catccagtct attaattgtt gccggaagc tagagtaagt 1680
agttcggcag ttaatagttt ggcgaacgtt gttggcattt ctacaggcat cgtgggtgtca 1740
cgctcgctgt ttggtatggc ttcattcagc tccggcccc aacgatcaag gcgagttaca 1800
tgatccccca tgggtgcaaa aaaagcggtt agtccttcg gtcctccgat cgttgcaga 1860
agtaaggttgg ccgcagtgtt atcactcatg gtatggcag cactgcataa ttctcttact 1920
gtcatgccat ccgtaagatg cttttctgtt actggtgagt actcaaccaa gtcattctga 1980
gaataccgcg cccggcgacc gagttgtct tgccggcgta caatacggga taatagtgt 2040
tgacatagca gaactttaaa agtgctcatc attggaaaac gttctcgaaa gcgaaaactc 2100
tcaaggatct taccgctgtt gagatccagt tcgatgtaa ccactctgtc acccaactga 2160
tcttcagcat ctttacttt caccagcggt tctgggtgag caaaacagg aaggcaaat 2220
gccgcaaaaa aggaaataag ggcgacacgg aaatgttga tactcataact cttcttttt 2280
caatattatt gaagcattt tcagggttat tgcgtcatga gcggtacat atttgaatgt 2340
atttagaaaa ataaaacaat aggggttccg cgcacattt cccgaaaagt gccacctgac 2400
gtctaagaaa ccattattat catgacattt acctataaaa ataggcgat cacgaggccc 2460
tttcgctctcg cgcgttctgg tgatgacggt gaaaacctct gacacatgca gtcggggag 2520
acggtcacag ctgtctgtt agcggatgtcc gggagcagac aagccgtca gggcgcgtca 2580
gcgggttgg ggggtgtcg gggctggctt aactatgcgg catcagagca gattgtactg 2640
agagtgcacc atatgcgtt tgaaataccg cacagatgcg taaggagaaa ataccgcata 2700
aggcgaatt gtaaacgtt atattttgtt aaaattcgct taaaatattt gttaaatcag 2760
ctcattttt aaccaatagg ccgaaatccgg caaaatccct tataaatcaa aagaatagac 2820
cgagataggg ttgagtgttgc ttccagttt gacaagagt ccactattaa agaacgttgg 2880
ctccaaacgtc aaaggcgaa aaaccgtcta tcagggcgat ggccactac gtgaaccatc 2940
acccaaatca agtttttgc ggtcgaggtg ccgtaaagct ctaatcgga accctaaagg 3000
gagccccga ttttagagctt gacggggaaa gccggcgaac gtggcgagaa aggaaggaaa 3060
gaaagcgaaa ggagcggcg ctagggcgct gcaagtgtt gcggtcacgc tgccgttaac 3120
caccacaccc gccgcgttta atgcgcgtt acagggcgcc tccattcgcc attcaggctg 3180
cgcaactgtt gggagggcg atcggtcggt gctcttcgc tattacgcca gtcggcgaaa 3240
gggggatgtg ctgcaaggcg attaagggtt gtaacgcgg gttttccca gtcacgcgt 3300
tgtaaaacga cggccagtgtt attgtataac gactcaactat agggcgaatt caaaaaaaaacc 3360
ctcaagaccc gtttagagggc cccaaagggt tatgctagtg aattctgcag gttaccggg 3420
gatccctctag agatccctcg acctcgagat ccattgtgtt gaaaagcctt tgccaggctg 3480
gcaagccacg tttgggtgtt gcgaccatcc tccaaaatca acaagttgtt aaaaaaaaaagc 3540
aggctatgcc aagtacatgt cgattgcgtt cgcgttgcgtt atgttgcgt tgtagtgc 3600
taccagcagt caaattgttgc tggagagtgc gtttttacat tatccctca tcctgattac 3660
gacaattttc agctgttctc gtccttacat ctctcttcat tgcacaatg gtcggaaatct 3720
tcttccttgc tgcatgttca tccaaaatcgaa catccaaaatg aatttcacgaa tattatccat ggtgtcgat 3780
tcttcctcat gattccatct acatatgtt tcctcaactt atattcgctc atcaatctca 3840
acgttatcac gtggggaaact cgtgaagctg tcgctaaggc aacgggacaa aagacgaaaa 3900
aagcgccat ggaacaattt taatcagttt tcgggagaag aaggaacatg aagagagacg agagaaaaatg gaaaagaaaa 4020
tgcagagaat ggagctagcc aattataat ttatccat gttggatgtt cttaacttt agaaatgtga 4080
agaaggagaa acgtgaagaa gaaactcaaa ctgcagattt tccgatttgc gagaacgttag 4200
agaagactca aaaagagatt cagaaggcata accgttatgt gtggatgtaca agtcatacg 4260
tgaaagtttg tgaacgagga aaactgaaaa gtgcggaaaa gttttctgg aacgagctca 4320
tcaatgcata tctgaaaccg atcaagacga cggcagctga aatgaaagcc gtcgcccgaag 4380
gattggcttc tctacgaaat cagattgtt tcactattct tctcgtaat tctcttcttg 4440
ctcttgccat ctttttgcattt cagaaacaca aaaatgtgtt cagcatcaag ttctcgccaa 4500
tcagtaagca atattacctt tatggtcaat tcaaaaaatt tttttttttt ttcttagaaaa 4560
cttccgatgg acgaaaaatga atgagatgac tgacaatac gaggaaaccg atgaaccatt 4620
aaaaatagat ccacttgaa tggaaattgt tggatgttgc ttaattattc tttttgttca 4680
aactctcgga atgcttctcc a 4701

<210> 7

<211> 25

<212> DNA

10

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide primer C04H5.6F

<400> 7

tgctcagaga gtttctcaac gaacc

25

<210> 8

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer C04H5.6R

<400> 8

caatgttagt tgcttaggacc acctg

25

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bF

<400> 9

cagccgatct ccgtcttgtg

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bR

<400> 10

ccgagggcaa gacaacgaag

20

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer Y57G11C.15F

<400> 11

accgtggtagt tcttatggag ctcg

24

<210> 12

11

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer Y57G11C.15R

<400> 12
tgcaagtggat tgggtcttcg

20

<210> 13
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer T25G3.2F

<400> 13
ggggacaagt ttgtacaaaa aaggcaggcta tgccaaagtac atgtcgattg cg

52

<210> 14
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer T25G3.2R

<400> 14
ggggaccact ttgtacaaga aagctgggtt ggagaagcat tccgagagtt tg

52